← Back to Search

Vitamin Supplement

Nicotinamide Riboside for Peripheral Arterial Disease

Phase 1 & 2
Waitlist Available
Research Sponsored by University of Oklahoma
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosis of PAD
Intermittent claudication
Must not have
Pharmacologically uncontrolled type 2 diabetes, hypercholesterolemia, hypertension
Current or prior cerebrovascular complications (including large vessel ischemic stroke with chronic functional impairment)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 weeks
Awards & highlights
No Placebo-Only Group

Summary

This trial aimed to see if taking a daily 1g supplement of NR for 4 weeks can improve blood vessel function, brain blood flow, and cognitive function in older adults with peripheral artery disease.

Who is the study for?
This trial is for older adults with peripheral artery disease (PAD). It's designed to see if a supplement called Nicotinamide riboside (NR) can improve blood flow and brain function. The eligibility criteria are not fully listed, but typically include having PAD and being of a certain age.
What is being tested?
The study tests the effects of taking 1 gram daily of Nicotinamide riboside (NR) over four weeks on blood vessel health in the legs, brain blood flow, and cognitive abilities in patients with PAD.
What are the potential side effects?
Since this summary doesn't list specific side effects, generally NR is considered safe but could potentially cause mild issues like nausea or indigestion. Participants will be monitored for any adverse reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with peripheral artery disease (PAD).
Select...
I experience leg pain when I walk.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My diabetes, high cholesterol, or high blood pressure is not well-controlled with medication.
Select...
I have had a stroke or other major brain blood flow problems.
Select...
I have a neurodegenerative disease.
Select...
I have been diagnosed with major depressive disorder.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Blood collection
Change in Attention
Change in Episodic Memory
+7 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: NR supplementationExperimental Treatment1 Intervention
1g daily NR
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nicotinamide riboside
2021
Completed Phase 3
~390

Find a Location

Who is running the clinical trial?

University of OklahomaLead Sponsor
472 Previous Clinical Trials
93,635 Total Patients Enrolled
8 Trials studying Peripheral Arterial Disease
1,380 Patients Enrolled for Peripheral Arterial Disease
~3 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top